Changan Huitong portfolio firm Diyi Group wins R&D 100 Award for CybeRay Pro platform

PUBT · 2d ago
Changan Huitong portfolio firm Diyi Group wins R&D 100 Award for CybeRay Pro platform
  • Changan Huitong portfolio company Diyi Group’s CybeRay Pro platform won a 2026 R&D 100 Award in the US.
  • CybeRay Pro was described as the first Chinese large-scale medical device to win the award, selected from thousands of entries.
  • Changan Huitong led a strategic CNY 350 million investment in Diyi Group in 2023 to support R&D, commercialization.
  • Diyi Group said CybeRay Pro is FDA-cleared for real-time image-guided gamma radiosurgery, targeting sub-millimeter precision ablation.
  • Diyi Group holds 75.8% domestic market share in gamma knife systems, reflecting scale in China’s radiotherapy equipment segment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Changan Huitong Group Co Ltd published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein.